HOME       Contact Us      Hire Us       Domestic Airlines        Railway Enquiry     Railway Booking     Hotels & Flights Abroad
NEIGHBOURS CALLING:      Dubai      Malaysia     Nepal     Bhutan
indiatraveltimes.com
COVID DATA Sept 18, 2021 INDIA: New Cases: 35,662 Total Cases:3,34,17,390 New Deaths: 281 Total Deaths: 4,44,529 New Tests: 14,48,833 Total Tests: 55,07,80,273 New Vax: 2,15,98,046 Total Vax: 79,42,87,699 Hot Spot States (daily deaths above 10) Karnataka: New Deaths: 18 Total Deaths: 37,573 Kerala: New Deaths: 131 Total Deaths: 23,296 TPR: 18.05% Maharashtra: New Deaths: 67 Total Deaths: 1,38,389 Tamil Nadu: New Deaths: 17 Total Deaths: 35,288 - India Travel Times.Com   [Estd: 1998]       * * *    Travel, More Travel, Travel Means A Million Things     * * *    
Covid vaccine Novavax is found safe, 90% effective in US trials
The results of the clinical trials of covid vaccine Novavax done in the US, Mexico and the UK are out. It has a high success rating similar to Pfizer and Moderna. Additionally, the UK trial demonstrated high efficacy against the Alpha variant strain too. Once approved by India, SII will start producing the Indian version called Covavax in September.

WASHINGTON, June 15: The Novavax covid vaccine, NVX- CoV2373, has demonstrated 90.4% efficacy, on par with Pfizer and Moderna's, in preventing symptomatic covid infection, according to the NIH.

The phase 3 clinical trial enrolling 29,960 adult volunteers in the US and Mexico has shown that the vaccine candidate demonstrated 90.4% efficacy in preventing symptomatic infection and 100% protection against moderate and severe covid.

In India, the bridging trials will be completed very soon. By September-December, Serum Institute of India (SII), which has a partnership with Novavax, plans to produce 20 cr doses of the vaccine, which will be called Covavax in India, and subsequently raise the output.

The trials in the UK on 15,000 adults also proved its safety and efficacy. In addition, the UK trial also demonstrated high efficacy against the Alpha variant strain of SARS-CoV-2. The UK is reportedly facing a third wave of the pandemic involving the highly transmissible Alpha variant.

According to the NIH press release, in people at high risk like those above 65 years and those under 65 years with certain comorbidities or with likely regular exposure to covid, the vaccine showed 91.0% efficacy in preventing symptomatic infection.

Mild-to-moderate injection site pain and tenderness were the most common local symptoms among the participants, and fatigue, headache and muscle pain lasting less than two days were the most common systemic symptoms.

The biotech firm, Novavax, Inc., of Gaithersburg, Maryland, was funded by the US in the research and development of the vaccine. The vaccine is made from a stabilized form of the coronavirus spike protein using the company’s recombinant protein nanoparticle technology, the statement said.

The vaccine is administered as two intramuscular injections 21 days apart and can be stored and handled at above-freezing temperatures.

Novavax said on Monday it will file for FDA approvals for regular licence in the third quarter for its vaccine, a full BLA approval. Since there are enough stocks of Moderna, Pfizer and J&J vaccines for all Americans, it is felt that there is no urgency now to issue an emergency use authorisation (EUA) for a new vaccine. The FDA had said so recently.

Therefore, it is also speculated that the Government may donate the new vaccine to needy countries.

However, Novavax president and CEO Stanley C. Erck told CNBC that there will be a large market in the US itself for booster shots. Stanley said researchers are beginning to see levels of antibodies wane after 6 to 12 months. He also sees a market in WHO's COVAX and mentioned India, as the country undergoing the worst scenario.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Stanley said in a statement on Monday.

Novavax said it is on course to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter.

The Novavax share prices registered a 7% rise in stock markets following the release of the results of the phase 3 clinical trials.

Note: The covid variants include B.1.1.7 (Alpha/first detected in the United Kingdom); B.1.351 (Beta/South Africa); B.1.427/B.1.429 (Epsilon/California); P.1 (Gamma/Japan and Brazil). There are also: B.1.525 (Eta/U.K. and Nigeria); B.1.526 (Iota/New York); B.1.526.1 (New York); B.1.617 (India); B.1.617.1 (Kappa/India); B.1.617.2 (Delta/India); B.1.617.3 (India); and P.2 (Zeta/Brazil).

Previous Files
ARCHIVES



Neighbours
Calling

Bhutan
Nepal
Malaysia
Dubai

Dalai Lama discharged from hospital in New Delhi
Fashion & Lifestyle
Yoga & Asanas
Fairs, Festivals & Melas
Religion & Cult
Pilgrimage
Art & Culture
History, Legends & Mythology
Ayurveda
Free Ayurveda Consultation
ARCHIVES
A Window On India
Fashion & Lifestyle
Yoga & Asanas
Fairs, Festivals & Melas
Religion & Cult
Pilgrimage
Art & Culture
History, Legends & Mythology
Ayurveda
News (Archives)
Travel News
Travel News Archives
Travel News Index

Custom Search